Benjamin Halladay, Chief Financial Officer at Esperion Therapeutics, Inc. (ESPR), sold 7,229 shares at $1.15 ($8K) on 2025-06-17, disclosed to the SEC on 2025-06-18.
Open-market sale of $8k ESPR by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| ESPR | SELL | 2025-12-18 | $27K | — | Filing → |
| ESPR | SELL | 2025-09-18 | $20K | — | Filing → |
| ESPR | SELL | 2025-07-18 | $12 | — | Filing → |